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Studying and modulating schizophrenia-associated
dysfunctions of oligodendrocytes with patient-speciﬁc cell
systems
Florian J. Raabe1,2, Sabrina Galinski1, Sergi Papiol 1,3, Peter G. Falkai1, Andrea Schmitt1,4 and Moritz J. Rossner1
Postmortem studies in patients with schizophrenia (SCZ) have revealed deﬁcits in myelination, abnormalities in myelin gene
expression and altered numbers of oligodendrocytes in the brain. However, gaining mechanistic insight into oligodendrocyte (OL)
dysfunction and its contribution to SCZ has been challenging because of technical hurdles. The advent of individual patient-derived
human-induced pluripotent stem cells (hiPSCs), combined with the generation of in principle any neuronal and glial cell type,
including OLs and oligodendrocyte precursor cells (OPCs), holds great potential for understanding the molecular basis of the
aetiopathogenesis of genetically complex psychiatric diseases such as SCZ and could pave the way towards personalized medicine.
The development of neuronal and glial co-culture systems now appears to enable the in vitro study of SCZ-relevant neurobiological
endophenotypes, including OL dysfunction and myelination, with unprecedented construct validity. Nonetheless, the meaningful
stratiﬁcation of patients before the subsequent functional analyses of patient-derived cell systems still represents an important
bottleneck. Here, to improve the predictive power of ex vivo disease modelling we propose using hiPSC technology to focus on
representatives of patient subgroups stratiﬁed for genomic and/or phenomic features and neurobiological cell systems. Therefore,
this review will outline the evidence for the involvement of OPCs/OLs in SCZ in the context of their proposed functions, including
myelination and axon support, the implications for hiPSC-based cellular disease modelling and potential strategies for patient
selection.
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INTRODUCTION
Schizophrenia (SCZ) is a severe, disabling neuropsychiatric
disorder with a lifetime prevalence of 0.3%–2.3%.1–4 The
substantial disability associated with this disorder, together with
its early onset and chronicity, places an enormous burden on
patients. This burden was quantiﬁed in the Global Burden of
Disease Study 2013, which found a remarkably high number of
disability-adjusted life years (DALY) and years lived with disability
(YLD) in SCZ compared with other medical conditions.5–7 The
clinical features of SCZ have been subdivided into positive,
negative and cognitive symptoms. Positive symptoms are likely to
be associated with a hyper-dopaminergic state. Neuroleptics that
act mainly at the dopamine receptor 2 (DRD2), which is highly
expressed in the basal ganglia, are effective in reducing positive
symptoms in many patients.8 An increasing body of evidence
indicates that negative and cognitive symptoms are functionally
associated with an excitation/inhibition dysbalance in the function
of glutamatergic and ɣ-aminobutyric acid (GABA)ergic synapses.
This dysbalance is proposed to eventually lead to a disconnection
of critical cortico-cortical and cortico-subcortical projection
systems, although the underlying mechanisms are not fully
understood.9 No effective pharmacological treatment is available
for negative and cognitive symptoms.8
So far, all attempts to target the synapse-associated glutama-
tergic system have failed and thus other mechanisms need to be
explored to identify novel treatment options.10 The lack of human
neurobiological test systems to study the consequences of genetic
and pharmacological perturbation, for example, has been a major
limitation in the ﬁeld of psychiatry to date. Research has been
mainly restricted to peripheral tissues, such as blood, correlative
imaging studies, genetics and molecular and histological analyses
of postmortem brain samples. Taken together, these approaches
have revealed strong evidence for a synaptic dysfunction. In
addition, current evidence of altered white matter (WM) structures
and reduced myelin gene expression in SCZ suggests that
dysfunctional oligodendrocyte precursor cells (OPCs) and/or
oligodendrocytes (OLs) may also contribute to the dysconnectivity
of brain regions seen in this disorder.11–14 Moreover, despite
compelling advances in the understanding of genetic factors that
contribute to the risk for SCZ, little is still known about the ﬁnal
mechanistic consequences of such risk factors in the biological
systems involved in the genesis of SCZ.15–17
The unavailability of proper model systems to accurately assess
the functional consequences for and contribution of dedicated
molecular and cellular signatures to these disorders is one
possible reason for the lack of biological insight. Animal models,
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especially inbred genetic mouse models, are well-suited to
characterize the molecular and phenotypic (i.e. behavioural)
impact of one or a few risk genes but cannot capture the
complex genetic risk architecture of SCZ. However, recent
developments in the methodologies for the induction of
pluripotent stem cells and their differentiation into neuronal and
glial cell types have paved the way for the generation of patient-
speciﬁc cellular systems.18–20 These systems hold promise for
comparing cellular phenotypes in patients and healthy controls,
whereas keeping the individual genomic risk background of each
individual. Likewise, such cellular models have some character-
istics that make them especially well-suited to assessing how
pharmacological treatments may restore affected pathways in
patient-speciﬁc cell types.21,22
This review aims to (i) revisit dysfunctions of OPCs/OLs in SCZ,
including and beyond myelination, and (ii) discuss strategies for
patient selection towards stem-cell generation and cellular
modelling as a pre-requisite to target OPC/OL deﬁcits with
pharmacological approaches.
OLIGODENDROCYTE DYSFUNCTION AND WHITE MATTER
DEFICITS IN SCHIZOPHRENIA
Neurodevelopment, myelination and axonal support
Puberty and adolescence are vulnerable periods of brain
development and are characterized by a multitude of psychosocial
challenges related to work and interpersonal relationships.
Adolescence coincides with the average age of onset of affective
and non-affective psychoses.23 The hypothesis that SCZ is not a
neurodegenerative but a neurodevelopmental disease that alters
brains circuits was proposed nearly 40 years ago24,25, but was
recently rediscovered and is gaining increasing inﬂuence.26–29
An important process that takes place during early postnatal
human brain development is myelination. The development of
WM tracts occurs at a high rate in the ﬁrst years of childhood and
continues during puberty and even young adulthood.30,31
Postmortem analyses of human brain tissues have revealed that
myelination follows a deﬁned chronological and topographical
order along the caudal to rostral axis.32,33 The fact that associative
cortical areas such as the prefrontal cortex are among the latest to
become myelinated, i.e. not until early adulthood, and are
generally less myelinated has potential implications for SCZ.14
The developmental aspects of myelination that may be affected in
SCZ remain largely unclear, however, because most studies have
been performed in adult postmortem samples.34 Defects in
myelination during development could be caused by a failed or
delayed differentiation of the OPC lineage and/or by failed or
delayed OL maturation. On the other hand, myelin deﬁcits in SCZ
could also reﬂect failures in the adaptive mechanism termed
‘myelin plasticity’. It has been known for a long time that electrical
activity stimulates myelination and that many structural aspects of
myelin-axon interactions can modulate for example conduction
velocity, including myelination per se; myelin thickness; the
spacing and size of the nodes of Ranvier and the clustering of
ion channels.35 It has recently been established that several of
these mechanisms are plastic and likely to contribute to the
overall plasticity of the brain.36 In addition, segmented or partial
myelination and the pattern and relationship of myelination by
individual OLs of functionally distinct or potentially synchronized
axons (coupled myelin bundles) have been mentioned as being
important, as yet unanswered questions in the ﬁeld that add
additional opportunities for remodelling and plasticity.37 Finally,
disturbances in myelination impair connectivity and coherence
between brain regions by causing improper spike timing and
desynchronized signal processing.38,39 Thus, the consequences of
deﬁcits in developmental and adaptive myelination align well with
the prevailing hypothesis of schizophrenia as a ‘dysconnectivity
disease’.40 More recently, OLs have been proven to metabolically
support axons,41,42 an essential biological mechanism that is
important for brain function and that can be uncoupled from
myelination. Myelination coincides with the maturation of brain
networks, which is mainly driven by the integration of interneur-
ons into local cortical microcircuits. It has thus been hypothesized
that, in addition to optimizing action potential ﬁdelity, the
segmented myelination of fast-spiking parvalbumin-positive
(Parv+) interneurons may help to cope with the high energy
demands of these cells.43 Strikingly, in the cortex of rodents most
myelinated axons of interneurons belong to the Parv+ subtype.44
The suggestion that dysfunctions of Parv+ interneurons are
associated with SCZ also led to the idea that failure of both
processes, i.e. optimizing of action potential ﬁdelity and metabolic
support, may together precipitate the network dysfunctions
associated with SCZ.45 However, this view was recently challenged
because the most comprehensive analysis of the contribution of
cell type-associated SCZ risk variants so far did not point to an
involvement of Parv+ interneurons in the aetiology of SCZ, but
rather highlighted the role of reelin-positive cortical interneur-
ons.46 Also, neither OPC- nor OL-speciﬁc gene sets were enriched
in SCZ risk genes identiﬁed in genome-wide association studies
(GWASs).46 Although these observations cannot be considered as
deﬁnitive, they suggest that OL dysfunctions in SCZ may rather be
a secondary consequence of genetic risk factors operating
primarily in glutamatergic neurons. This does not, however,
exclude ‘myelin plasticity’ as a potential target for research into
treatment options. On the other hand, a study where glial
precursors isolated from childhood-onset SCZ patients were
transplanted into mice also provided evidence for a direct and
‘primary’ contribution of OLs to SCZ47 (see below for details).
Disturbed oligodendrocyte function and myelin: impact on
cognition in schizophrenia
A series of studies with different techniques provided much
evidence for disturbed OL function and myelin deﬁcits in
schizophrenia, which has been reviewed in detail elsewhere.12,34
In short, in vivo brain imaging studies revealed decreased
fractional anisotropy as a sign of impaired WM tract integrity,48,49
a lower myelin water fraction in the WM of the frontal lobe and
corpus callosum50 and functional dysconnectivity in relevant
neuronal networks,51 which is supported by electrophysiological
measurements.40 Studies in SCZ patients that combined imaging
and neurocognitive testing revealed associations between
impaired cognitive performance and decreased fractional aniso-
tropy,52,53 disturbed connectivity54,55 and reduced volume of
speciﬁc brain areas (hippocampus and nucleus accumbens).56
Furthermore, histopathological ﬁndings in postmortem brain
tissue indicated a decreased number of OLs in the dorsolateral
prefrontal cortex (DLPFC) and cornu ammonis (CA) 4 region of the
anterior and posterior hippocampus,57–59 and reduced OL number
was correlated with cognitive dysfunction.60 Moreover, a reduced
density of perineuronal OLs,61 lower myelin basic protein (MBP)
immunohistochemical staining intensities62 and damaged myelin
sheaths and apoptosis of OLs63,64 have also been documented in
light microscopy and electron microscopy studies. Transcriptomic
studies in postmortem tissues reported reduced expression of
myelin- and OL-related genes, such as MAG and MBP, in several
relevant brain regions,65,66 and myelin-associated proteins have
been shown to be decreased in proteomic studies.67,68
Taken together, accumulating evidence suggests that distur-
bances of OL function and myelination likely contribute to the
dysconnectivity of brain regions and cognitive impairments seen
in SCZ. Whether the deﬁcits in OL functions and their impact on
cognition is a primary causative mechanism or a secondary
consequence of neuronal and synaptic alterations, or both, is still
unclear, although evidence exists for both options.46,47
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GENETIC AND CELLULAR COMPLEXITY OF SCZ - NEW
INTERPRETATIONS FROM THE LATEST GWASS AND SCRNASEQ
ANALYSES
GWASs and exome sequencing approaches have provided
outstanding and solid results regarding the role of common and
rare genetic variations in psychiatric disorders, such as SCZ. In SCZ,
an increasing number (so far around 150) of genetic risk loci have
been unequivocally identiﬁed after controlling for multiple testing
and for sources of confounding, such as population stratiﬁca-
tion.16,17,69 Likewise, these studies have provided compelling
evidence of the polygenic architecture of this disorder. Polygenic
risk scores (PRSs) can be calculated for everyone and summarize in
a single risk score the effects of many single nucleotide
polymorphisms (SNPs) under an additive model. PRSs have shown
an excellent replicability across independent samples of SCZ
patients, although they lack predictive value as regards disease
risk.70
An important proportion of loci associated with SCZ contain at
least one expression quantitative trait locus (eQTL) for a gene
within 1 Mb. Active brain enhancers are enriched in these
associations, highlighting the regulatory nature of such associa-
tions with SCZ risk. Further analysis revealed that several risk SNPs
are associated with genes of known regulatory function in
neurons and also with genes relevant for glial cells and OPCs/
OLs.16,17,71–73 SCZ risk variants are enriched within genomic
regions that are marked by histone H3-K4 methylation (H3K4me3),
which points to the impact of processes related to the control of
gene expression.73 Pathway analyses have shown the aggregation
of risk variants in pathways related to neuronal signalling,
postsynaptic density, FMRP-bound transcripts and mitochondrial
and glial function.74,75 Interestingly, Duncan et al. revealed a
stronger association of an expert-curated glia-OL pathway
(comprising 52 genes) with SCZ than with bipolar disorder.74
Worth mentioning in this context is the fact that, numerically,
most pathway analyses underline the best evidence of disturbed
neuronal function in SCZ.
The contribution of brain cell types to SCZ was recently
addressed in a sophisticated analysis combining the most
comprehensive list of SCZ GWAS hits with a series of single cell
(sc) and single nucleus (sn) RNAseq analyses from mouse and
human brain tissues, which provide dramatically enhanced cell-
type resolution.46 In contrast to the previous, above mentioned
pathway analyses, which relied on lists of expert curated cell type
markers,74,75 Skene et al.46 computed cell type-speciﬁc gene
expression metrics on the basis of scRNAseq and snRNAseq data.
Moreover, they weighted risk gene contributions for genetic
association probabilities on the basis of GWAS data. With this
approach, the group made several observations with respect to
brain cell types associated with SCZ: (i) cell-type proﬁles from
mature (e.g. pyramidal and cortical interneurons) but not from
immature cell types (e.g. neuronal progenitors, radial glia) were
associated with SCZ; (ii) a dedicated set of mature neuronal cell
types (medium spiny neurons, cortical and hippocampal gluta-
matergic projection neurons and cortical GABAergic interneurons)
showed greater association with SCZ than any other neuronal and
glial cell type; and (iii) human, but not mouse, reference mRNA cell
type proﬁles indicated that OPCs and OLs also showed a moderate
enrichment. These observations likely helped to shape the current
hypotheses on SCZ aetiology, which highlight late cortical
developmental processes, including microcircuit maturation
(‘micro-connectivity’), rather than early neurodevelopmental
processes. Moreover, the association of gene sets from cortical
and hippocampal projection neurons support the idea that the
connectivity between brain regions (‘macro-connectivity’) may
also be critical. Because both ‘micro-connectivity’ and ‘macro-
connectivity’ essentially depend on trophic support and myelina-
tion (see above), it appears possible that the ‘intermediate’
enrichment of OPC-/OL-speciﬁc gene sets further supports these
assumptions. Although the analyses by Skene et al.46 made use of
the most comprehensive data sets available so far, the conclusions
of their study are not deﬁnite because of some technical
limitations: (i) non-cell type-speciﬁc gene sets may operate to a
variable, disease-relevant extent in different cell types (e.g.
alteration of gene expression by the H3-K4 methylation pathway,
see above); (ii) so far, human brain region- and cell type-speciﬁc
RNA reference proﬁles are only available as nuclear transcrip-
tomes, which generates a bias on transcripts involved in cellular
processes, such as those associated with dendrites and/or
synapses (compartmentalized transcription has also been
described in cellular processes of OLs76,77); and (iii) although
scRNAseq and snRNAseq data sets offer an unprecedented cell
type deﬁnition and resolution, in general the depth of sequencing
per individual transcriptome is low and low abundance transcripts
coding for transcription factors or signalling components, for
example, may be underrepresented. Besides these limitations, the
above ﬁndings give the impression that common risk variants of
SCZ primarily target dysfunctions of striatal and cortical neurons,
which may cooperate with a minor fraction of risk factors
operating in OPCs/OLs to disturb the local and remote con-
nectivity of brain networks (Fig. 1).
PHENOMICS-BASED PATIENT STRATIFICATION
On the phenomics side, the use of a case-control condition as a
target phenotype has inherent limitations, including patient
heterogeneity and overlap of the symptom spectrum. A poten-
tially more promising strategy might be to use alternative or
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Fig. 1 Primary and secondary cell types and mechanisms of
schizophrenia (SCZ)—combining results of the latest genome-wide
association studies (GWASs) with cell type-speciﬁc transcriptomics.
Most recent GWASs combined with single-cell RNAseq proﬁles
identiﬁed SCZ risk genes that may primarily operate in three
neuronal cell types: GABAergic medium spiny neurons (cyan),
glutamatergic pyramidal neurons (red) and GABAergic cortical
interneurons (blue). A minor fraction of single nucleotide poly-
morphisms associated with increased risk for SCZ may affect
oligodendrocyte precursor cells (OPCs) and oligodendrocytes and
their function (yellow). Nonetheless, oligodendroglia intensively
interact with pyramidal projection neurons and cortical interneur-
ons at the level of myelination and metabolic support. Myelination
of long-range projection neurons supports the connectivity
between brain regions (‘macro-connectivity’). Myelination and
trophic support of interneurons may support the function of local
circuits (’micro-connectivity’). Therefore, we hypothesize that the
disturbed functional connectivity in SCZ results from the interaction
of cell types and mechanisms where the primary effects occur (e.g.
directed at synapses in glutamatergic and GABAergic neurons), with
secondary effects on OPCs and oligodendrocytes ﬁnally causing
white matter alterations. It is tempting to speculate that (i) positive
symptoms are likely more connected to the dysfunction of
dopamine-responsive medium spiny neurons and (ii) excitation-
inhibition dysbalances of cortical glutamatergic and GABAergic
neurons and disturbed connectivity, including oligodendroglia
functions, may rather be associated with higher order cognitive
impairments and negative symptoms
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additional (sub)phenotypes within these patients that may be
closer to the aetiological roots of psychotic disorders.78
Cognition-based patient stratiﬁcation
Cognitive impairments are a key aspect of SCZ79 and an attractive
but still mainly untapped target for drug development.29 Several
aspects of cognition, including working memory, attention and
executive performance, are affected in SCZ and are already
detectable in early-onset SCZ and high-risk individuals.80 More-
over, cognitive impairments that occur during the ﬁrst episode are
very stable and improvements or deteriorations are hardly
detectable in SCZ patients even after 10 years.81,82 Besides the
clinical aspects of cognitive impairment as one of the main
symptoms in SCZ, there is also a genetic relationship between
cognition and SCZ risk genes. Thus, an increased PRS for SCZ is
associated with reduced spatial visualization (measured by a block
design test) in a cohort of patients, relatives and healthy
controls.83 Assessment of cognitive abilities with the Brief
Assessment of Cognition in Schizophrenia (BACS) also showed
an association of PRS with cognitive performance in both SCZ
patients and healthy controls.84 Besides a general association
between increased polygenic risk for SCZ and impaired cognition,
a large study identiﬁed 21 independent SCZ risk loci that inﬂuence
cognitive functioning.85 Furthermore, cognitive performance was
found to be slightly worse in adult healthy carriers of risk copy
number variations that are associated with SCZ than in healthy
non-carriers.86,87 On the functional level, a higher PRS is associated
with hypoactivity in the prefrontal cortex during working memory
tests in healthy controls.88,89 Most recently, the largest GWAS on
human intelligence performed so far identiﬁed hundreds of genes
involved in this trait.90 The same study reported a negative
genetic correlation between intelligence and SCZ (rg=−0.21, P=
3.82 × 10−17). Remarkably, most prominent gene sets associated
with cognition are enriched in medium spiny neurons and
hippocampal projection neurons.90
In summary, this body of clinical and genetic evidence suggests
that cognitive dysfunction in SCZ is an integral part of the disorder
rather than a consequence of it. Therefore, using cognition as a
stratiﬁcation criterion for patient selection has the potential to
capture key elements in the genetic/molecular architecture of SCZ
that are measurable in cellular systems. The results of the
aforementioned studies based on SCZ PRS and cognition further
support this notion. However, the amount of variation in cognition
explained by the SCZ PRS is very modest, which strongly advises
against using it as the only patient selection criterion. Although
the SCZ PRS is currently the best measure of genetic risk available,
the score alone may not yet allow a proper stratiﬁcation of patient
subgroups for decisions regarding iPSC generation and follow-up
analyses.
Imaging-based patient stratiﬁcation
Patients with early-onset and ﬁrst-episode SCZ already display
widely distributed reduced WM homogeneity, as indicated by a
substantial reduction of fractional anisotropy in most brain areas,
including several ﬁbre tracts; this reduced WM homogeneity has
been associated with disturbed higher order cognitive func-
tion.53,91–93 These ﬁndings were recently veriﬁed by the largest
imaging study conducted so far, which analysed 29 independent
and international imaging studies that included a total of 4322
individuals with SCZ.94 Moreover, individuals at high risk for
psychosis already display altered WM integrity similar to the
pattern of ﬁrst-episode patients.95 Systematic reviews and meta-
analyses substantiate a pattern of WM impairments and structural
dysconnectivity in patients with early-onset SCZ, drug-naive
patients and clinical high-risk individuals96 and link disturbed
WM in ﬁrst-episode SCZ to cognitive deﬁcits.97 A pioneering study
identiﬁed a strong association between two risk SNPs in genes
important for OL function (MAG and OLIG2), the integrity of WM
tracts and cognitive performance.98 The use of genome-wide
analyses will likely provide stronger conﬁdence about which
genetic factors and pathways may link WM deﬁcits with cognitive
impairments in SCZ. In terms of identifying novel drug targets,
understanding the biological pathways that modulate the course
of the disease over time will provide additional opportunities
beyond current genetic approaches.99
Accumulating evidence suggests that WM pathology and
functional dysconnectivity are key aspects of SCZ pathophysiology
that contribute to cognitive impairments. Thus, the combined use
of phenotypes related to cognition and neuroimaging holds great
potential for patient stratiﬁcation and may be less affected by
experimental noise than current genetic classiﬁers. A critical issue
for improving selection strategies even further in the future could
be to include environmental stress factors, if available. The
additional stratiﬁcation tools, i.e. cognitive and imaging-related
phenotypes and environmental stress factors, might help to
identify representatives of (sub)groups with veriﬁed WM patho-
physiology and subsequently to investigate their underlying
mechanisms and their impact on cognition in SCZ, e.g. with
hiPSC-based cellular modelling (Fig. 2a).
GENERATION OF HIPSC-BASED NEUROBIOLOGICAL CELL
SYSTEMS
Until recently, most insights into psychiatric diseases, including
SCZ, have been generated from postmortem tissue samples, brain
imaging, genetic and pharmacological studies and animal models.
Cellular reprogramming methods now provide a new opportunity
to model the complex polygenetic conditions in diseases such as
SCZ by generating patient-derived hiPSC-based systems.
Generation of hiPSCs from patients
The ﬁrst successful reprogramming into iPSCs was performed with
murine ﬁbroblasts101 and was awarded the Nobel Prize in
Physiology or Medicine 2012. Multiple subsequent studies in
humans successfully reprogrammed diverse somatic cell types
that are more accessible than ﬁbroblasts, such as keratinocytes,102
urine cells103 and (cord) blood samples.104–108 Peripheral blood
mononuclear cells (PMBCs) can be reprogrammed even after
cryopreservation.109 Initial reprogramming methods relied on
constitutive retroviral and lentiviral expression systems that were
limited by insufﬁcient genomic integration and insertional
mutagenesis.110 In recent years, integration-free reprogramming
methods have been developed on the basis of adenovirus,111
mRNA,112 sendai virus113 and episomal vectors.114 Episomal
reprogramming is highly reliable for different somatic cell lines,
and the rapid loss of the reprogramming factors from the host
genome over short time periods makes this method highly
attractive.115 For translational clinical research, it is crucial to
choose the best reprogramming method and the most suitable
primary cell type, i.e. the cell type that is most easily accessible
and can be stored for long periods.116 Because PMBC sampling
and cryopreservation are standard procedures and less invasive
than skin biopsies, PBMCs represent the best choice for human
cell-based studies on psychiatric diseases. Moreover, setting up
large PBMC repositories for clinical studies is a routine procedure
that might allow post hoc access to patient data, e.g. for validation
purposes beyond the ‘subgroup representatives’ selected in ﬁrst-
round reprogramming. Thus, the use of PBMCs (e.g. CD34+
hematopoietic stem cells and erythroid progenitor cells)117–119
and episomal reprogramming enables hiPSCs to be generated in a
safe, efﬁcient and scalable approach.
Once generated, hiPSCs can be differentiated in principle to all
speciﬁc brain cell types by providing a lineage-speciﬁc chemical
environment and/or transient overexpression of transcription
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factors that determine the cell lineage. Protocols have been
developed for hiPSC-derived neuronal stem cells (iPSC NSCs),
hiPSC-derived glutamatergic and GABAergic neurons (hiPSC
neurons), hiPSC astrocytes, hiPSC OPCs and hiPSC OLs (see
below). The generation of disease-relevant cell types represents a
major step forward in studying aspects of the neuronal and glial
contribution to SCZ in 2D or 3D cellular systems without losing the
genetic complexity (Fig. 2b).
Differentiation of hiPSCs to neuronal cells
The most prominent cell types with signiﬁcant importance in the
modelling of psychiatric diseases are the hiPSC neurons. By using
different protocols, glutamatergic excitatory neurons can be
generated with similar properties as those of the cortex120 and
hippocampus.121 Speciﬁc overexpression of certain transcription
factors alone,122,123 or in combination with small molecules,124
enables more homogeneous and scalable populations of gluta-
matergic iNeurons to be obtained. Besides excitatory neurons,
stem cells can also be differentiated into cortical GABAergic
interneurons similar to medium spiny striatal interneurons125 or
Parv+ interneurons.126,127 For more details, we refer readers to
comprehensive reviews on the differentiation of iPSC-derived
neurons120 and iPSC-derived astrocytes128 or microglia.129
Differentiation of hiPSCs into the oligodendroglial lineage
The initial approaches employed to generate ‘ﬁrst-generation’
OPCs from stem cells used small molecule cocktails that inhibited
or activated restrictive signalling pathways. These approaches are
comprehensively reviewed in detail elsewhere.130–132 In general,
the main disadvantages of such chemical differentiation
approaches are the very protracted protocols, which can take up
to several months and are expensive, the high variability in the
generated OPCs and the limited numbers of differentiated cells
produced with the desired properties. Consequently, these
approaches are hardly suitable for diagnostic and empirical
perturbation purposes. Another strategy to generate OPCs/OLs is
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Fig. 2 Principals of patient stratiﬁcation for subsequent human-induced pluripotent stem cell (hiPSC-)-based cellular disease modelling
combining genetics, white matter pathology and cognitive impairments. a Subsets of SCZ risk genes (as indicated by the red part of the DNA
symbol) impair cognitive performance. Red human icons illustrate such risk gene carriers. Recent evidence suggests that the effect of these
‘cognitive’ risk genes is at least in part connected to white matter pathology. Sufﬁcient patient stratiﬁcation is needed to reveal the
underlining mechanisms of white matter pathology. Clinical deep phenotyping, with a focus on neurocognitive testing, combined with
imaging of white matter is probably a suitable approach to identify the corresponding subgroup of patients. Additional stratiﬁcation based on
cell-speciﬁc PRSs might further increase stratiﬁcation precision. b hiPSC technology enables the generation of a toolbox of patient-derived cell
systems. Monocultures of glial cells and neurons and myelinating co-culture systems may simulate disease-relevant aspects of SCZ in 2D and
3D cellular systems in vitro. Moreover, hiPSC-derived cells can be tested in chimeric mouse models in vivo. NB: The illustrations of the ‘chimeric
mouse’ and the DNA ‘risk alleles’ have been published previously100
Studying and modulating schizophrenia-associated dysfunctionsy
F.J. Raabe et al.
5
Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2018)    23 
the forced overexpression of lineage-determining transcription
factors (as pioneered for iNeurons, see above). Rodent ﬁbroblasts
have been successfully trans-differentiated in this way.133,134
Furthermore, several combinations of certain transcription factors
can differentiate hiPSCs or predifferentiated hiPSC NSCs into
iOPCs and iOLs relatively quickly and efﬁciently (Table 1).
Thus, several combinations of stage-speciﬁc transcription
factors seem to be sufﬁcient to differentiate hiPSCs into the
OPC/OL lineage by directed overexpression. The studies listed in
Table 1 used different combinations of transcription factors and
applied different cell media and supplement compositions.
Although the major focus of Pawlowski et al. and Rodrigues
et al. was to generate and characterize the iOPC stage,137,138 Li
et al., Ehrlich et al. and García-León et al. tried to reach the iOL
stage as part of the main protocol.135,136,139 Indeed, it is unclear
whether protocol differences may have affected the properties of
iOPCs or iOLs, e.g. with respect to kinetics and the efﬁciency of
differentiation and myelination. Thus far, no study has compared
the protocols by applying a comprehensive battery of molecular
and morphological assessments, but such a study could help to
identify potential (dis)advantages of the different conditions.
Myelinating 2D culture systems
hiPSC OPCs and hiPSC OLs not only express state-speciﬁc markers,
but are also able to myelinate axon-like structures,136 human
foetal neurons140 and hiPSC neurons.136,139 They can be used in
co-culture systems to investigate axoglial interactions or, for
example, to assess pro-myelinating drugs with potential relevance
also for SCZ. After pioneer experiments in mouse pluripotent
epiblast stem-cell-derived OPCs,141 studies have also shown that
clobetasol, miconazole and pranlukast promote myelination of
hiPSC OPCs136,139,141 (Fig. 2B).
Myelinating 3D culture systems
As a highly advanced in vivo test system, hiPSC OPCs have been
used in human-mouse chimeric models. hiPSC OPCs have the
capacity to myelinate mouse brain slices ex vivo139 and brain
regions in living animals.136,138,140 Chimeric hiPSC-based systems
thus allow glial pathophysiology to be investigated in complex
organisms up to the behavioural level (Fig. 2B).47 Newly developed
3D cell culture systems enable disease biology to be studied at the
circuit level in an experimentally accessible and complex cellular
environment.142,143 The 3D organoid culture systems, termed
cerebral organoids, recapitulate some critical features of human
cortical development. To date, maturation of circuits by spine
pruning or myelination cannot be studied in cerebral organoids
because of the lack of OLs and microglia.144
Another, technically ‘less challenging’ approach uses hiPSC-
derived cortical spheroids, which consist of a cerebral cortex-like
structure and include astrocytes and interneurons.145 Recently,
Madhavan et al. generated hiPSC-derived ‘oligocortical spher-
oids’,146 in which 20% of the contained cell were part of the
oligodendroglial linage after 14 weeks of maturation. Early-stage
myelination of neurons occurred after 20 weeks, but myelin
maturation, reﬁnement and myelin compaction were not com-
plete until 30 weeks of maturation. Thus, higher level processes
such as myelination can be studied in 3D hiPSC-derived cerebral
spheroids. However, the time and costs of generating them are
still quite challenging.
An additional, less complex but much faster approach is the
generation of an hiPSC-derived 3D brain microphysiological
system (BMPS).147 The key accelerating step in this approach is
the pre-differentiation of hiPSC to hiPSC NSCs before the 3D
generation of the BMPS. In just 2 weeks Pamies et al.148 generated
a BMPS that contained GABAergic, dopaminergic and glutama-
tergic neurons, astroglia and oligodendroglia. Intriguingly, this
approach allowed Pamies et al. to observe complex processes
such as synaptogenesis and myelination within only 4 weeks, and
42% of axons were myelinated after 8 weeks. The above
mentioned pioneering studies have limitations regarding intra-
and inter-individual variability, cellular robustness, reproducibility,
scalability and affordability. However, the ﬁeld of 3D cellular
systems, as well as the whole-hiPSC ﬁeld, is rapidly evolving. Thus,
in the near future we might expect more robust protocols for 3D
hiPSC-based cell systems that contain OPCs and OLs (Fig. 2B).
RECENT OBSERVATIONS AND CHALLENGES OF PATIENT-
SPECIFIC NEUROBIOLOGICAL TEST SYSTEMS
The landmark study by Brennand et al. in 2011 that characterized
hiPSC neurons from SCZ patients was performed in a mixed
population of glutamatergic, dopaminergic and GABAergic
neurons that showed decreased neuronal connectivity, decreased
neurites and decreased levels of post-synaptic protein PSD95.148
Recent studies have focused more on speciﬁc neuronal subtypes,
such as pyramidal cortical interneurons, cortical interneurons and
dentate gyrus (DG) granule neurons; these studies are reviewed in
detail elsewhere.20,149
Table 1. Fast differentiation of human-induced pluripotent stem cells (hiPSCs) or predifferentiated hiPSC neuronal stem cells (NSCs) to induced
oligodendrocyte precursor cells (iOPCs) or induced oligodendrocytes (iOLs) by using selected expression of transcription factors
Cells used Transcription factors Generated cell stage Days References
hiPSCs SOX10, OLIG2 iOPC (PDGFRα+/O4+) 14 Li et al.135
iOL (CNP+) 42
hiPSC NSCs SOX10, OLIG2, NKX6.2a iOPC (O4+) 28 Ehrlich et al.136
iOL (MBP+/CNP+) 35
hiPSCs SOX10, OLIG2 iOPC (PDGFRα+/O4+) 10 Pawlowski et al.137
iOL (MBP+/PLP+/CNP+) 20
hiPSCs NKX2.2 pre-iOPC (PDGFRα+) 30 Rodrigues et al.138
iOPC (O4+) 55
hiPSCs SOX10a iOL (O4+/MBP+/PLP+) 22 García-León et al.139
aBest combination of transcription factors to reach (different) endpoint
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Disturbed OPC/O function and impaired myelination in SCZ-
relevant iPSC cell systems
In contrast to the large number of studies on hiPSC-derived
neurons, so far only a few studies have investigated the
oligodendroglial impact in SCZ-related iPSC models. Chen et al.
focused on the known schizophrenia risk gene FEZ1 in murine and
human iPSC-derived oligodendroglial cells and showed that FEZ1
knockdown impaired OL development150. Additional analysis
revealed that potential SCZ-relevant pathways governed FEZ1
expression and post-transcriptional stability150. Lee et al. used
hiPSC neurons and hiPSC OPCs from two individuals with a large
(289 kb) heterozygous deletion in CNTNAP2 that affected exons
14–15, whereby both the patient with SCZ and the patient’s
healthy father, who carried the allele, were heterozygous.151 The
research group showed that the expression of exons 14–15 was
signiﬁcantly decreased in hiPSC-derived neurons and OPCs, but
not in ﬁbroblasts, whereas the expression of other exons was
upregulated, indicating cell-type-speciﬁc mechanism.151 Another
family-based approach investigated the contribution of two rare
missense mutations in CSPG4 (A131T and V901G).152 CSPG4 codes
for NG2, a marker of proliferating OPCs, which are frequently
termed NG2-glia.153,154 hiPSC OPCs derived from CSPG4 mutation
carriers revealed dysregulated posttranslational processing, differ-
ent cellular NG2 location, impaired OPC survival and reduced
differentiation to mature OLs.152 Transfection of the two risk
variants into OPCs generated from healthy non-carrier siblings
revealed similar deﬁcits, underlining the contribution of the
described mutations to the OPC pathology. By using diffusion
tensor imaging (DTI), the investigators observed impairments of
white matter integrity in affected mutation carriers but not in
unaffected siblings or the general population.152 Interestingly, no
pathological signs were detected in carrier-derived hiPSC neurons,
underlining the OPC-speciﬁc effect of the CSPG4 mutations.152
These studies were either prototypical, hypothesis-driven or
single-gene interference approaches or they evaluated ‘rare’
variants that are thought to reﬂect high-penetrance and ‘high-
impact’ mutations; thus, the studies are limited in their dissecting
mechanisms and restricted to the dysfunction of a single gene or
locus. The generation of iPSCs and derived cell systems from
patients who are carriers of polygenic risk assemblies could enable
a deeper understanding of common molecular roots of SCZ in a
given cell type, such as OLs. Moreover, the differentiation
protocols applied in the studies mentioned above were solely
based on small molecule differentiation protocols, which may be
compromised by having a higher level of variability than directed
protocols. Nonetheless, direct cell lineage conversion may possibly
override subtle developmental deﬁcits, which may be better
accessible with chemical protocols (see below).
In the seminal study by Windrem et al., glial precursor cells,
which could mature into both oligodendroglial and astroglial
lineage cells, were generated from patients with childhood-onset
SCZ and unaffected controls.47 SCZ-derived precursor cells
displayed impaired glial maturation, altered transcriptomic
signatures in vitro and hypomyelination; when grafted into brains
of immune-deﬁcient mice, the mice showed psychosis-related
behaviours, such as deﬁcits in sensory motor gating.47 This study
provides the strongest evidence so far that glial precursor cells
have a cell-autonomous effect that is thus a potentially ‘primary’
cause of the disease or at least contributes to it. It seems likely that
the majority of SCZ-relevant endophenotypes detected by Wind-
rem et al. were caused by glial dysfunction and related to
disturbed myelination and impaired functional connectivity.
Nonetheless, more studies are needed to dissect the relative
impact of the cell-type-dependent risk in individual patients.
Challenges for the future of disease-relevant cell systems
To date, hiPSC-based studies in psychiatric disorders have mainly
been performed on adherent monolayer cultures and have
focused on cell-autonomous molecular and cellular abnormalities.
Most protocols applied to generate neuronal cell types also
contained cells of mixed temporal and spatial identities and other
cell types of glial and non-neural origin.155 The large hetero-
geneity of these mixed cell cultures leads to a substantial and
hard-to-control level of variability, even when the cells are
obtained from the same individual, and decreases the conﬁdence
and robustness of the results (i.e. observed SCZ vs. control
samples). One very costly and potentially impracticable strategy to
tackle this issue is to increase the technical and biological
replicates.156 Another, possibly more feasible strategy to increase
levels of reliability is to reduce the cellular heterogeneity of hiPSC-
based cell systems. This may be possible by the directed
generation of cell types via overexpression of deﬁned cell- and
stage-speciﬁc transcription factors, as described above. These
paradigms may bypass certain maturation processes, which might
be a disadvantage when studying psychiatric diseases, in which
neurodevelopmental aspects are hypothesized to play a role, such
as SCZ. As regards SCZ, however, recent analyses of GWAS data
did not provide evidence for a strong association between early
developmental cell stages and the disease (see above46).
Although great progress has been made with 3D cell-based
neurobiological model systems, they still have major limitations.
Current protocols for organoids mimic early neurodevelopment
but lack mature OLs and do not develop to postnatal maturation
stages, including myelination and synapse pruning. However,
recent landmark studies have managed to generate myelinating
spheroids and brain microphysiological systems and we can
expect more elaborated protocols in the future. One of the current
challenges is to develop procedures to establish more mature 3D
cell systems. For both 2D and 3D cell systems, scalability is an
important issue to enable genetic and chemical screenings at high
throughput. Another important topic is intra- and inter-patient
variability.157,158 To increase reliability, multiple hiPSC clones
should be analysed. An alternative strategy could be to initially
focus on a pool of clones and to subsequently validate the
obtained effects in individual cell clones to substantiate robust
ﬁndings. In any case, modern array-based genotyping tools should
be applied to verify the genomic integrity and genotype beyond
karyotyping at the chromosome level.
Even if further progress is made in 2D and 3D cellular systems,
they will always be limited regarding construct validity in brain
disorders where circuit-level dysfunctions precipitate behavioural
and cognitive deﬁcits. We must accept that even patient-speciﬁc
cellular models, which reﬂect the genetic background of an
individual, only allow us to study certain disease-associated
endophenotypes, such as axonal support or multiple aspects of
myelination, in isolation. The possibility to generate iOLs and
myelinating 3D systems with patient-derived OLs simply will
expand the experimental repertoire in psychiatric research.
PATIENT SELECTION AS A PRE-REQUISITE TO OVERCOME THE
BOTTLENECK OF LIMITED HIPSC-BASED CELLULAR TEST
SYSTEMS
One of the major questions that researchers face is how to select
representatives of subgroups from whom hiPSC will be derived for
empirical testing. An approach that may yield successful results is
to use different analytical methods to select individuals according
to phenotypical characteristics. This approach requires the
availability of deeply phenotyped samples. Whereas selection
based on a simple clinical feature may have limitations, clustering
individuals according to different clinical subdomains (e.g.
psychopathology, neurocognition or response to treatment) and
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imaging (e.g. DTI) may yield more valid clusters of individuals with
an enhanced biological validity, similar to the Research Domain
Criteria (RDoC) concept.159,160 Moreover, including longitudinal
information into such a clustering will undoubtedly enrich the
validity of the clusters in terms of disease progression/trajectory
and potentially also treatment response. However, an important
limitation of this approach is the high degree of uncertainty
regarding the role of the environment in determining the clinical
and neurocognitive proﬁle of a patient. Another method of
selecting patients is to leverage the current knowledge on the
genetic architecture of complex disorders, such as SCZ.78 Given
their polygenic nature, one could select those individuals who are
carriers of the largest/lowest genetic burden on the basis of their
individual PRS and subsequently analyse the characteristics of
their cellular systems.78 Such a polygenic score could also be
biologically informed on the basis of pathways or cell-type
information (cell-type-speciﬁc PRS). This approach would be
extremely relevant if the hypotheses and cellular systems are
based on a speciﬁc cell type (Fig. 2B). Here again, however, caution
is advised when using the PRS as a stratiﬁcation criterion, given
the modest amount of variation in clinical diagnosis explained by
SCZ PRS.
Imaging techniques might allow patients with impaired white
matter tract integrity to be included; these patients might hold the
promise of having oligodendroglial pathology, which could be
conﬁrmed by combining imaging with cognitive proﬁling, for
example. The subsequent generation of hiPSC cell systems will be
very labour- and cost-intensive and represents the bottleneck in
the process. This strongly argues for a stringent, at best
hypothesis-driven pre-selection of relevant subgroup
representatives, which might enable investigators to reveal
corresponding molecular mechanisms in SCZ. There is a chance
that hiPSC technology might be a future key technology to ﬁnd
new cellular targets by performing genetic and chemical
perturbation screenings with relevance for a given subgroup
and/or trait, even with very limited numbers of test systems.
Ideally, subsequent validation of candidate drugs in clinical trials
and approved treatment should be restricted to those patients
who ﬁt the initial classiﬁers used for ‘empirical validation’, such as
white matter abnormalities combined with cognitive deﬁcits (Fig.
3).
OUTLOOK
The advent of hiPSCs combined with the generation of in principle
any neuronal or glial cell type holds great potential for ex vivo
disease modelling. A wide range of disease modelling iPSC-based
systems have been developed, ranging from 2D monocultures to
complex 3D myelinating multicellular systems, and we can expect
that many more protocols and conditions will be explored in the
future. However, the high costs and cellular variability are
important limitations and represent crucial challenges, as does
the issue of reproducibility. Besides these technical limitations,
meaningful patient stratiﬁcation is another important issue to be
addressed in the future. Despite important limitations and
challenges, in principle hiPSC-based cellular disease modelling
offers a possibility to address cellular phenotypes in patients with
SCZ, whereas retaining the genetic background of each individual.
This approach, however, requires stringent experimental proof of
the stability of the respective genotype throughout the process of
reprogramming, cell-line establishment and differentiation. Unfor-
tunately, experiments to prove stability have not yet been
implemented in the ﬁeld. Epigenetic signatures may also
introduce an as yet unknown layer of variability. Nonetheless,
the decrease in costs for genomic and epigenetic proﬁling
technologies should allow the ﬁeld to cope with these sources
of variability when setting up batteries of iPSC lines that may
complement clinical studies. If successful, personalized strategies
that include these new technologies might help to address old
questions and reveal new molecular pathways that contribute to
neuropsychiatric diseases such as SCZ161 and might also enable
targeted drug development.162 The ﬁeld of hiPSC technology in
neuroscience is rapidly evolving and constantly progressing. We
are witnessing a new era of psychiatry research that brings new
challenges, new solutions and new possibilities.
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Fig. 3 hiPSC models are the bottleneck for molecular validation of
hypotheses driven by genome-wide association studies (GWASs).
Analyses based on GWASs (n > 100,000 individuals) in combination
with clinical investigations allow for deﬁnition of causal hypotheses
in complex diseases, such as SCZ. The next major step is sufﬁcient
patient stratiﬁcation for the genetic subtype and corresponding
subphenotype (n > 100). Subsequent iPSC reprogramming from the
identiﬁed representative patients remains the bottleneck because
the process is so cost and labour intensive. hiPSC models enable
experimental validation and evaluation of GWAS-driven hypotheses.
These patient-derived cell systems allow researchers to screen
treatment options and pave the way for new therapies that can be
introduced after being veriﬁed in clinical studies with increasing
numbers of patients; these studies are best performed in patient
subgroups that align with the initial stratiﬁcation strategy
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